Silvio Danese
Humanitas University
Internal medicineSurgeryIntensive care medicineAdverse effectImmunologyVedolizumabInflammationInfliximabInflammatory bowel diseaseDiseaseCrohn's diseaseMEDLINEAdalimumabUlcerative colitisIn patientClinical trialBiosimilarMedicineBiologyGastroenterology
1,105Publications
100H-index
29.6kCitations
Publications 933
Newest
#1Lucie Weislinger (University of Lorraine)
#2Lucas Guillo (University of Lorraine)H-Index: 1
Last. Luc Frimat (University of Lorraine)H-Index: 30
view all 9 authors...
BACKGROUND AND AIM 5-Aminosalicylic acid (5-ASA) nephrotoxicity is a rare and idiosyncratic condition in patients with inflammatory bowel disease (IBD), which may lead to end-stage kidney failure. Kidney function monitoring is recommended in clinical practice to prevent this complication. However, no data is available regarding the knowledge and adherence of patients with IBD to this monitoring. METHODS As a part of routine practice, patients with IBD under treatment or previously treated with 5...
Source
Source
#1Pablo OliveraH-Index: 8
#2Stéphane ZuilyH-Index: 9
Last. Patrick Lacolley (University of Lorraine)H-Index: 61
view all 19 authors...
Patients with inflammatory bowel disease (IBD) are at increased risk of thrombotic events. Therapies for IBD have the potential to modulate this risk. The aims of this Evidence-Based Guideline were to summarize available evidence and to provide practical recommendations regarding epidemiological aspects, prevention and drug-related risks of venous and arterial thrombotic events in patients with IBD. A virtual meeting took place in May 2020 involving 14 international IBD experts and 3 thrombosis ...
Source
#1Virginia Solitano (Humanitas University)H-Index: 2
#2Tommaso Lorenzo Parigi (Humanitas University)H-Index: 6
Last. Silvio Danese (Humanitas University)H-Index: 100
view all 4 authors...
INTRODUCTION Despite huge and increasing developments in the treatment of inflammatory bowel disease (IBD), a significant percentage of patients with Crohn's disease (CD) and ulcerative colitis (UC) is still in need of an effective and safe therapeutic option. Tackling the trafficking of leukocytes specifically within or directed to the inflamed gut appears to be a particularly promising strategy, and several new anti-integrin agents are currently under investigation in clinical trials. AREAS CO...
Source
#1Mina Hassan-Zahraee (Pfizer)H-Index: 11
#2Zhan Ye (Pfizer)
Last. Jie Quan (Pfizer)H-Index: 3
view all 23 authors...
Background null The first-in-class treatment PF-06480605 targets the tumor necrosis factor-like ligand 1A (TL1A) molecule in humans. Results from the phase 2a TUSCANY trial highlighted the safety and efficacy of PF-06480605 in ulcerative colitis. Preclinical and in vitro models have identified a role for TL1A in both innate and adaptive immune responses, but the mechanisms underlying the efficacy of anti-TL1A treatment in inflammatory bowel disease (IBD) are not known. null Methods null Here, we...
Source
#1Severine Vermeire (Katholieke Universiteit Leuven)H-Index: 146
#2Geert R. D'Haens (UvA: University of Amsterdam)H-Index: 76
Last. Chunlin Chen (Millennium Pharmaceuticals)
view all 13 authors...
Background and aims null Report results from VISIBLE 2, a randomised, double-blind, placebo-controlled phase 3 trial evaluating a new subcutaneous [SC] vedolizumab formulation as maintenance treatment in adults with moderately to severely active Crohn's disease [CD]. null Methods null Following open-label vedolizumab 300 mg intravenous induction therapy at Weeks 0 and 2, Week 6 clinical responders (≥70-point decrease in CD Activity Index [CDAI] score from baseline) were randomised 2:1 to receive...
Source
#1Bénédicte Caron (University of Lorraine)
#2Ferdinando D'Amico (Humanitas University)H-Index: 14
Last. Laurent Peyrin-Biroulet (University of Lorraine)H-Index: 103
view all 4 authors...
Randomized clinical trials are the gold standard for new drugs development. Clinical trials became increasingly complex, in particular in the field of inflammatory bowel diseases. For this reason, a new study design called "cluster randomized trial" has been introduced. Cluster randomized trials randomly assign groups of individuals within a population of interest, such as people in a particular research site, clinic, or hospital, and measure the effects of an intervention at the individual leve...
Source
#1Gionata Fiorino (Humanitas University)H-Index: 51
#2Mariangela Allocca (Humanitas University)H-Index: 20
Last. Silvio Danese (Humanitas University)H-Index: 100
view all 3 authors...
Source
#1Michele Carvello (Humanitas University)H-Index: 10
Last. Antonino Spinelli (Humanitas University)H-Index: 41
view all 7 authors...
BACKGROUND AND AIMS Few recent studies focus on the treatment of rectal cancer in patients with ulcerative colitis. We report treatment options and results for this subset of patients with a multimodal approach at two European referral centers. METHODS Ulcerative colitis patients diagnosed with rectal cancer arising at less than 15 cm from the anal verge between January 2010 and December 2020 were analyzed. Demographics, clinical data, details of medical and surgical treatment were retrieved fro...
Source
#1Bénédicte Caron (University of Lorraine)
#1Bénédicte Caron (University of Lorraine)H-Index: 1
Last. Laurent Peyrin-Biroulet (University of Lorraine)H-Index: 103
view all 4 authors...
BACKGROUND AND AIMS Since the 1980s, many studies have evaluated the efficacy of therapies to improve the outcomes of patients with perianal Crohn's disease. We performed a systematic review to describe the evolution of endpoints in perianal fistulizing Crohn's disease. Efficacy outcomes, definitions, and measurements tools were assessed. METHODS Electronic databases were searched up to 1 st November 2020. All published randomized placebo-controlled trials enrolling patients with perianal fistul...
Source